Q-omics provides the consensus-scored MIR3945 profile across patient tissues and cancer cell-line models. MIR3945 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, MIR3945 is differentially expressed in 3, with the highest sampling consensus in LUSC. Additionally, MIR3945 RNA expression shows 5,558 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KICH, LUSC, and STAD as cancer lineages where MIR3945 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR3945 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR3945 survival associations across molecular data types. MIR3945 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR3945 RNA expression–survival associations across cancer types. High MIR3945 expression shows unfavorable associations in KICH, STAD, LUSC, KIRP and BLCA, but favorable associations in LUAD. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for MIR3945 RNA expression.
This table summarizes MIR3945 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR3945. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR3945 shows lower tumor expression in LUSC and LUAD and higher tumor expression in ESCA. The LUSC box plot shows higher MIR3945 RNA expression in normal versus tumor tissue (log2 FC = −0.871, t-test p < 0.001).
This table shows molecular features associated with MIR3945 in patient tissues and cancer cell lines. In patient samples, MIR3945 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
